Rozzini et al. evaluated the influences of the serum concentration of albumin on cognitive response to AChEI, finding significant changes in ADAS-Cog in favor of the low (≤ 4 g/dl) vs. high (>4.5 g/dl) albumin level group at 3 and 15 months in AD patients treated with donepezil. Here, ALB is linked to Alzheimer disease.